Biogen Idec Inc., a Weston biotechnology company known for its multiple sclerosis drugs, said Tuesday that it is seeking regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.
Current treatments on the market can require a patient to get three or four injections a week. The hope for Biogen Idec’s treatment is that a patient would need only one or two injections per week. If approved, the treatment would be the first major advance for hemophilia A patients in more than two decades, Biogen Idec said.
In a dtetailed press release, the company said it has submitted a Biologics License Application to the US Food and Drug Administration for the marketing approval of recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.